je.st
news
New Studies Investigating the Use of KEYTRUDA (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
2015-11-17 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. First-Time Presentation of KEYTRUDA Compared to Chemotherapy in Advanced Non-Small Cell Lung Cancer From KEYNOTE-010 Study New Findings of KEYTRUDA in Novel Combinations with Other Immunotherapies in Advanced Melanoma First-Time Findings in Multiple Myeloma and ER-Positive/HER2-Negative Breast Cancer as Well as New Findings in Classical Hodgkin Lymphoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
presented
studies
solid
Category:Biotechnology and Pharmaceuticals